Trial · NCT03929029
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Nivolumab Lead-In (Weeks 1-12) | STARTED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 6 | |
| Nivolumab Lead-In (Weeks 1-12) | STARTED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 5 | |
| Nivolumab Lead-In (Weeks 1-12) | COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 6 | |
| Nivolumab Lead-In (Weeks 1-12) | COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 5 | |
| Nivolumab Lead-In (Weeks 1-12) | NOT COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 0 | |
| Nivolumab Lead-In (Weeks 1-12) | NOT COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 0 | |
| Nivo, NeoVax, Ipilimumab (Weeks 12-21) | STARTED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 5 | |
| Nivo, NeoVax, Ipilimumab (Weeks 12-21) | STARTED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 5 | |
| Nivo, NeoVax, Ipilimumab (Weeks 12-21) | COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 5 | |
| Nivo, NeoVax, Ipilimumab (Weeks 12-21) | COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 5 | |
| Nivo, NeoVax, Ipilimumab (Weeks 12-21) | NOT COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 0 | |
| Nivo, NeoVax, Ipilimumab (Weeks 12-21) | NOT COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 0 | |
| Nivolumab (Week 24+, Every 4 Weeks) | STARTED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 4 | |
| Nivolumab (Week 24+, Every 4 Weeks) | STARTED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 4 | |
| Nivolumab (Week 24+, Every 4 Weeks) | COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 4 | |
| Nivolumab (Week 24+, Every 4 Weeks) | COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 4 | |
| Nivolumab (Week 24+, Every 4 Weeks) | NOT COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) | 0 | |
| Nivolumab (Week 24+, Every 4 Weeks) | NOT COMPLETED | Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03929029/flow